CONNOR OVERBY: Open Payments
NPI 1386340198 · CULLMAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,768 in 97 payments from 9 companies in 2025. Trend: 2023 $1,493 · 2024 $1,442 · 2025 $1,768
Food & beverage: $1,677Education: $91
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 25 | $404 |
| Neurocrine BioSciences, Inc. | 17 | $334 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $271 |
| Lundbeck LLC | 10 | $222 |
| Teva Pharmaceuticals USA, Inc. | 8 | $213 |
| Otsuka America Pharmaceutical, Inc. | 8 | $138 |
| ABBVIE INC. | 5 | $87 |
| Janssen Pharmaceuticals, Inc | 4 | $80 |
| Alkermes, Inc. | 1 | $19 |
Products named: COBENFY, INGREZZA, CAPLYTA, ABILIFY MAINTENA, REXULTI, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
